# Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

Study · id `cardio:ct-nct07588438` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07588438](<https://clinicaltrials.gov/study/NCT07588438>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07588438

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT07588438. Non-randomized; no masking; primary purpose treatment. Start 2026-07-27 (anticipated); primary completion 2027-08-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT07588438, source copy `cardio:ctgov-nct07588438-2026-05-19`, retrieved 2026-10-26)
- Planned start: 2026-07-27 (anticipated) (ClinicalTrials.gov record NCT07588438, source copy `cardio:ctgov-nct07588438-2026-05-19`, retrieved 2026-10-26)
- Primary completion: 2027-08-10 (anticipated) (ClinicalTrials.gov record NCT07588438, source copy `cardio:ctgov-nct07588438-2026-05-19`, retrieved 2026-10-26)
- Completion: 2027-08-10 (anticipated) (ClinicalTrials.gov record NCT07588438, source copy `cardio:ctgov-nct07588438-2026-05-19`, retrieved 2026-10-26)
- Countries: Paraguay (ClinicalTrials.gov record NCT07588438, source copy `cardio:ctgov-nct07588438-2026-05-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07588438-2026-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
- Acronym: REAL-TIRZEPY
- Condition: Obesity
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
- Lead sponsor: Las Rías Medical Center
- Lead sponsor class: OTHER
- Collaborator: LABORATORIO DE PRODUCTOS ETICOS C.E.I.S.A
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: 1635e7af3f02f7bd75853500dd39b0a8f090c82560ac722dcf40d98f6768d8e9
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
